Diadem’s goal is to be the first truly blood-based Prognostic (Px) test for early detection of dementia in Neurodegenerative disease with a particular focus to Alzheimer’s Disease. Diadem has developed a unique/novel solution to one of the biggest problems in Neurodegenerative disease and in particular in early, accurate, predictive, fast, non-invasive and cost effective diagnosis in Alzheimer’s disease, which should enable improve treatment and the overall improvement in patient treatment/outcomes. Diadem was founded in 2012 as a spin-off of University of Brescia (Italy) and preparing for rapid commercialisation of its product via a global launch with strategic partners in 2021, additionally the Company is planning to carrying out further retrospective and prospective clinical trials to further validate its clinical claims.